Androgen receptor (AR) degradation enhancer ASC-J9 ® in an FDA-approved formulated solution suppresses castration resistant prostate cancer cell growth

Authors:

Abstract
No abstract available
Funding Information
  • NIH (CA127300, CA156700)
  • Taiwan Department of Health Clinical Trial and Research Center of Excellence (DOH99-TD-B-111-004)
  • Shenzhen Municipal Government of China (ZD201111080117A)

This publication has 23 references indexed in Scilit: